Hosted on MSN
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 ...
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results